# OnCo record idea-sclc-subtype-directed (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-sclc-subtype-directed/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-sclc-subtype-directed" ;
  schema:name "Subtype-directed therapy for SCLC (ASCL1 / NEUROD1 / POU2F3 / inflamed)"@en ;
  schema:description "Small-cell lung cancer is at least four diseases under the microscope's uniform appearance. Treat each by its transcription-factor subtype."@en ;
  schema:url <https://onco.cc/ideas/idea-sclc-subtype-directed/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2307980>, <https://clinicaltrials.gov/study/NCT05740566> ;
  onco:related <https://onco.cc/roadmaps/lung-cancer-evidence-roadmap/>, <https://onco.cc/ideas/idea-lung-small-cell-platform-with-shared-controls-and-subtypes/> ;
  onco:cancers <https://onco.cc/cancers/sclc/> ;
  onco:targets <https://onco.cc/targets/dll3/>, <https://onco.cc/targets/bcl2/>, <https://onco.cc/targets/atr/>, <https://onco.cc/targets/parp/> ;
  onco:drugs <https://onco.cc/drugs/tarlatamab/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-dellphi-301-nejm-2023/>, <https://onco.cc/key-papers/paper-dll3-sclc-clin-cancer-res-2019/>, <https://onco.cc/key-papers/paper-tarlatamab-sclc-n-engl-j-med-2025/> .